Summary
The AI statements are about pricing/discount programs and do not map to the provided FDA-approved TOPAMAX prescribing information excerpts (indications, contraindications, dosing, warnings/precautions, drug interactions, adverse reactions, storage). No substantive on-label pharmacologic, safety, or administration claims were evaluated; therefore label alignment cannot be established.
Category Scores
Accurate Statements
Unsupported Statements
Without insurance, Topamax pricing typically depends on the pharmacy used and the prescription strength/quantity.
No pricing/insurance/discount information is present in the provided FDA label excerpts; cannot be supported by the supplied prescribing information.
Topamax pricing can vary based on whether the patient is getting brand-name Topamax or generic topiramate.
No pricing or brand-vs-generic cost comparison information is present in the provided FDA label excerpts.
Switching to generic topiramate can reduce the price compared with brand-name Topamax when clinically appropriate.
The provided label excerpts do not address consumer pricing or switching specifically framed as cost-reduction; cannot be supported by the supplied prescribing information.
Most pharmacies offer discount pricing through in-store programs, manufacturer discounts (when available), or third-party savings cards.
No content regarding pharmacy discount programs or manufacturer discount/savings cards in the provided label excerpts.
The exact savings from discount programs depends on the pharmacy and the program terms.
No discount-program terms or savings details exist in the provided FDA label excerpts.
In most cases, generic topiramate is the cheaper option compared with brand-name Topamax.
No market pricing or comparative cost statements are present in the provided FDA label excerpts.
Cash prices cannot be quoted accurately without prescription specifics.
No label content discusses how to quote cash prices or what prescription specifics affect pricing.
Pharmacies need prescription strength, form, quantity, and ZIP code to provide the true cash price because pricing varies by location and contract.
No label content discusses ZIP code/location/contract-based pricing determination.
A price comparison between brand-name Topamax and generic topiramate is affected by whether the prescription is specifically brand-name Topamax or an acceptable generic substitute.
No label content addresses pricing comparisons or how prescription branding/generic substitution affects cost.
Contradictions
Important Omissions
No on-label prescribing information was addressed (e.g., indications, dosage and administration, contraindications, boxed warnings, warnings/precautions, drug interactions, adverse reactions, monitoring, or storage/handling as applicable).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The response contains non-label pricing/discount guidance and does not include dosing, contraindications, warnings, interactions, or monitoring instructions that could directly lead to clinical misuse based on the provided label excerpts.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Mostly Aligned
Primary Issue
Statements are about pricing/discount programs and cannot be verified against the provided FDA-approved prescribing information.
Suggested Improvement
If evaluating against the FDA label, restrict claims to on-label sections (Indications 1, Contraindications 4, Dosage/Administration 2, Warnings/Precautions 5, Drug Interactions 7, Adverse Reactions 6, and Storage 16). For pricing, label alignment cannot be determined from the supplied excerpts.